A Phase 3 interventional study of Ethambutol hydrochloride and Clarithromycin in Mycobacterium Avium-Intracellulare Infection and HIV Infections, sponsored by Pharmacia. Completed at 44 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Pharmacia (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer — none open to participants now, none under way, none of them phase 3. Mycobacterium avium-intracellulare Infection · Pfizer.
Among the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer, this one is one of 3 in phase 3, and was the 1st registered.
66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.
Browse Mycobacterium avium-intracellulare Infection studies →None of the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer is open now. The open studies under Mycobacterium avium-intracellulare Infection, anywhere →
Of the 7 Mycobacterium avium-intracellulare Infection studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 95 across 44 interventional studies indexed under Mycobacterium avium-intracellulare Infection.
Median enrollment 585 across the 6 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pharmacia, one of the names counted as Pfizer. Under that name alone:
Pharmacia is the lead sponsor of 7 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Mycobacterium avium-intracellulare Infection by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To assess survival and comparative tolerability among the three treatment regimens.
Patients are randomized to receive clarithromycin and ethambutol plus either placebo or rifabutin at one of two doses. Treatment continues indefinitely. AS PER AMENDMENT 04/19/94: Doses of rifabutin have been lowered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Patients with the following prior condition are excluded:
History of to rifabutin, rifampin, erythromycin, clarithromycin, azithromycin, or ethambutol.
Prior Medication:
Excluded within 7 days prior to study entry:
Excluded within 14 days prior to study entry:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Jun 1999. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ethambutol · Clarithromycin · Rifabutin
Mycobacterium avium-intracellulare Infection →